Human IL-1α(Interleukin 1 Alpha) ELISA Kit
中文名称:人白介素1α(IL-1α)酶联免疫吸附测定试剂盒

Price:
- 反应性: Human
- 检测范围: 3.91-250 pg/mL
- 灵敏度: 2.35 pg/mL
产品应用 | ELISA |
检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人IL-1α抗体包被于酶标板上,实验时样品(或标准品)中的人IL-1α会与包被抗体结合。后依次加入生物素化的抗人IL-1α抗体和辣根过氧化物酶标记的亲和素,抗人IL-1α抗体与结合在包被抗体上的人IL-1α结合,生物素与亲和素特异性结合而形成免疫复合物,游离的成分被洗去。加入显色底物(TMB),TMB在辣根过氧化物酶的催化下呈现蓝色,加终止液后变成黄色。用酶标仪在450 nm波长处测OD值,IL-1α浓度与OD450值之间呈正比,通过绘制标准曲线计算出样品中IL-1α的浓度。 |
反应类型 | Sandwich-ELISA |
规格 |
96 T
/ 48 T
/ 96 T × 5
|
反应时间 | 3 h 30 min |
反应性 | Human |
检测方法 | 比色法;ELISA;夹心法 |
检测范围 | 3.91-250 pg/mL |
灵敏度 | 2.35 pg/mL |
样本体积 | 100 μL |
样本类型 | 血清、血浆或其他生物体液 |
特异性 | 可检测样本中的人IL-1α,且与其它类似物无明显交叉反应 |
精密度 | 板内,板间变异系数均<10% |
回收率 | 80%-120% |
储存条件 | 2-8℃ |
有效期 | 12个月 |
数据处理 |
-
Testing the regulatory framework in South Africa – a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis
IF: 2.688 -
Galectin-3, IL-1A, IL-6, and EGF Levels in Corneal Epithelium of Patients With Recurrent Corneal Erosion Syndrome
IF: 2.215 -
Inflammation-dependent ISG15 upregulation mediates MIA-induced dendrite damages and depression by disrupting NEDD4/Rap2A signaling
IF: 4.328Journal: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)PMID:30826466Reactivity:HumanSample Type:Serum -
Sapylin (OK-432) alters inflammation and angiogenesis in vivo and vitro
IF: 3.743Journal: BIOMEDICINE & PHARMACOTHERAPY (2019)PMID:30844656Reactivity:HumanSample Type:Wound drainage fluid -
Autoantibodies to a specific peptide epitope of human Hsp60 (ATVLA) with homology to Helicobacter pylori HspB in H.?pylori-infected patients
IF: 2.225 -
Overcoming the Heat Endurance of Tumor Cells by Interfering with the Anaerobic Glycolysis Metabolism for Improved Photothermal Therapy
IF: 13.942 -
Particulate matter 2.5 regulates lipid synthesis and inflammatory cytokine production in human SZ95 sebocytes
IF: 2.341Journal: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)PMID:28849137Reactivity:HumanSample Type:Cell culture supernatant -
The lncRNA MALAT1 protects the endothelium against ox-LDL-induced dysfunction via upregulating the expression of the miR-22-3p target genes CXCR2 and AKT
IF: 3.169